Boothbay Fund Management LLC Acquires New Shares in Cardiff Oncology, Inc. (NASDAQ:CRDF)

Boothbay Fund Management LLC acquired a new stake in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 129,960 shares of the company's stock, valued at approximately $564,000. Boothbay Fund Management LLC owned 0.25% of Cardiff Oncology as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CRDF. Adage Capital Partners GP L.L.C. acquired a new position in Cardiff Oncology during the fourth quarter worth $5,609,000. Geode Capital Management LLC boosted its stake in Cardiff Oncology by 5.9% in the 4th quarter. Geode Capital Management LLC now owns 982,878 shares of the company's stock worth $4,266,000 after buying an additional 54,646 shares during the last quarter. State Street Corp boosted its holdings in shares of Cardiff Oncology by 3.4% in the 3rd quarter. State Street Corp now owns 832,652 shares of the company's stock valued at $2,223,000 after purchasing an additional 27,628 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Cardiff Oncology by 68.7% in the 4th quarter. Bank of New York Mellon Corp now owns 288,615 shares of the company's stock worth $1,253,000 after purchasing an additional 117,514 shares during the period. Finally, Blair William & Co. IL grew its stake in Cardiff Oncology by 14.1% during the fourth quarter. Blair William & Co. IL now owns 282,025 shares of the company's stock worth $1,224,000 after buying an additional 34,947 shares during the period. Institutional investors and hedge funds own 16.29% of the company's stock.

Cardiff Oncology Stock Up 4.1 %

CRDF stock traded up $0.11 during trading on Friday, hitting $2.82. 693,525 shares of the company's stock traded hands, compared to its average volume of 1,122,591. Cardiff Oncology, Inc. has a 52 week low of $2.01 and a 52 week high of $5.64. The stock has a fifty day moving average price of $3.29 and a two-hundred day moving average price of $3.48. The stock has a market capitalization of $187.60 million, a price-to-earnings ratio of -3.00 and a beta of 1.81.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lifted their price objective on shares of Cardiff Oncology from $13.00 to $17.00 and gave the company a "buy" rating in a research note on Friday, February 28th.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.